{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023481","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.630508+00:00","generated_at":"2026-05-22T06:20:15.298018+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vericel records Q1 MACI revenue $46.3M (+15% YoY), raises FY profitability guidance","bullets":["Record Q1 MACI revenue $46.3M (+15% YoY); total revenue $52.6M vs $51.3M YoY.","Net loss $11.2M ($0.23/diluted) vs $3.9M loss ($0.08) YoY; adjusted EBITDA $3.2M vs $7.2M.","Full-year revenue growth reaffirmed 20-23%; raised gross margin guidance to 74% and adjusted EBITDA margin to 26%.","~400 MACI Arthro surgeons trained; YTD biopsy growth >30% for trained surgeons; NexoBrid +207% YoY.","Cash $162M, no debt; tariffs expected negligible impact."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023481","json":"https://secwatch.observer/filing/0001628280-25-023481.json","markdown":"https://secwatch.observer/filing/0001628280-25-023481.md","text":"https://secwatch.observer/filing/0001628280-25-023481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/0001628280-25-023481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/vcel-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T06:20:15.298018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}